Cash flow Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
0.9131 ^USD	+1.68%		+1.47%	-3.88%

Dec. 19	IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	CI
Dec. 10	Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	CI

5b36e1.pVf2nirz2fb2A3Pej8RVOF0tK5d6vhxi8_eJGwp0DCc.wC2p5lyHt5SVdyuq1ZJtWRAVTrpIjywpkZHdeU4nS0LdYLr2XaGYtMFsPg

Published financial data: IMUNON, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	500K	500K	500K	500K	-
Total Revenues	500K	500K	500K	500K	-
Cost of Goods Sold, Total	13.07M	11.34M	10.62M	11.73M	-
Gross Profit	-12.57M	-10.84M	-10.12M	-11.23M	-
Selling General & Admin Expenses, Total	8M	7.64M	10.89M	13.69M	9.74M
R&D Expenses	-	-	-	-	11.29M
Other Operating Expenses, Total	8M	7.64M	10.89M	13.69M	21.03M
Operating Income	-20.57M	-18.49M	-21.01M	-24.92M	-21.03M
Interest Expense, Total	-1.39M	-1.29M	-570K	-5.03M	-197K
Interest And Investment Income	501K	120K	11K	453K	1.16M
Net Interest Expenses	-893K	-1.17M	-559K	-4.58M	961K
Other Non Operating Income (Expenses)	29	7	1.9K	1.8K	-396K
EBT, Excl. Unusual Items	-21.46M	-19.66M	-21.56M	-29.5M	-20.47M
Merger & Related Restructuring Charges	-	-	-	-	-
Impairment of Goodwill	-	-	-1.98M	-	-
In Process R&D Expenses	-	-2.37M	-	-13.37M	-
Other Unusual Items	2.79M	-1.3M	1.39M	5.4M	-329K
EBT, Incl. Unusual Items	-18.67M	-23.33M	-22.15M	-37.47M	-20.8M
Income Tax Expense	-1.82M	-1.85M	-1.38M	-1.57M	-1.28M
Earnings From Continuing Operations	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M
Net Income to Company	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M
Net Income - (IS)	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M
Preferred Dividend and Other Adjustments	-	-	-	-	-
Net Income to Common Incl Extra Items	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M
Net Income to Common Excl. Extra Items	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M
Per Share Items
Net EPS - Basic	-11.58	-10.08	-3.83	-5.03	-2.16
Basic EPS - Continuing Operations	-11.58	-10.08	-3.83	-5.03	-2.16
Basic Weighted Average Shares Outstanding	1.46M	2.13M	5.43M	7.14M	9.05M
Net EPS - Diluted	-11.58	-10.08	-3.83	-5.03	-2.16
Diluted EPS - Continuing Operations	-11.58	-10.08	-3.83	-5.03	-2.16
Diluted Weighted Average Shares Outstanding	1.46M	2.13M	5.43M	7.14M	9.05M
Normalized Basic EPS	-9.21	-5.77	-2.48	-2.58	-1.41
Normalized Diluted EPS	-9.21	-5.77	-2.48	-2.58	-1.41
Supplemental Items
EBITDA	-19.84M	-17.74M	-20.3M	-24.19M	-20.78M
EBITA	-20.34M	-18.26M	-20.89M	-24.92M	-21.03M
EBIT	-20.57M	-18.49M	-21.01M	-24.92M	-21.03M
EBITDAR	-19.32M	-17.22M	-19.74M	-23.6M	-
Effective Tax Rate - (Ratio)	9.73	7.91	6.24	4.18	6.16
Current Domestic Taxes	-	-	-	-	-
Total Current Taxes	-	-	-	-	-
Deferred Domestic Taxes	-	-1.85M	-1.38M	-1.57M	-1.28M
Total Deferred Taxes	-	-1.85M	-1.38M	-1.57M	-1.28M
Normalized Net Income	-13.41M	-12.29M	-13.48M	-18.43M	-12.79M
Interest on Long-Term Debt	1.39M	1.29M	570K	5.03M	197K
Supplemental Operating Expense Items
General and Administrative Expenses	8M	7.64M	10.89M	13.69M	9.74M
Research And Development Expense From Footnotes	13.07M	13.72M	10.62M	25.1M	11.29M
Net Rental Expense, Total	522K	522K	561K	588K	-
Imputed Operating Lease Interest Expense	561K	616K	398K	3.67M	-
Imputed Operating Lease Depreciation	-38.82K	-93.79K	162K	-3.08M	-
Stock-Based Comp., COGS (Total)	900K	800K	1.4M	900K	-
Stock-Based Comp., R&D Exp. (Total)	-	-	-	-	200K
Stock-Based Comp., G&A Exp. (Total)	1.4M	1.1M	2.4M	1.8M	600K
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	2.3M	1.9M	3.8M	2.7M	800K

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	6.88M	17.16M	19.59M	11.49M	5.84M
Short Term Investments	7.99M	-	29.8M	21.25M	9.86M
Total Cash And Short Term Investments	14.86M	17.16M	49.39M	32.75M	15.7M
Other Receivables	21.37K	-	109K	129K	-
Total Receivables	21.37K	-	109K	129K	-
Restricted Cash	-	-	-	1.5M	-
Other Current Assets, Total	1.35M	1.66M	2.45M	2.78M	2.55M
Total Current Assets	16.24M	18.82M	51.95M	37.15M	18.24M
Gross Property Plant And Equipment	4.93M	4.57M	4.52M	3.35M	4.45M
Accumulated Depreciation	-3.1M	-3.23M	-3.36M	-2.64M	-2.1M
Net Property Plant And Equipment	1.84M	1.34M	1.17M	704K	2.35M
Goodwill	1.98M	1.98M	-	-	-
Other Intangibles, Total	16.08M	13.48M	13.37M	-	-
Deferred Tax Assets Long-Term	1.82M	1.85M	1.38M	1.57M	1.28M
Deferred Charges Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	333K	58.76K	6.18M	4.55M	50K
Total Assets	38.28M	37.53M	74.05M	43.98M	21.92M
Liabilities
Accounts Payable, Total	2.86M	2.24M	2.55M	3.59M	3.52M
Accrued Expenses, Total	1.83M	1.82M	1.77M	2.6M	1.95M
Current Portion of Long-Term Debt	1.84M	1.12M	-	1.42M	-
Current Portion of Leases	388K	433K	549K	231K	485K
Unearned Revenue Current, Total	500K	500K	500K	-	-
Other Current Liabilities	475K	636K	1.4M	2.2M	1.44M
Total Current Liabilities	7.89M	6.75M	6.77M	10.04M	7.39M
Long-Term Debt	7.96M	3.93M	5.85M	4.61M	-
Long-Term Leases	1.14M	710K	231K	-	1.14M
Unearned Revenue Non Current	1M	500K	-	-	-
Other Non Current Liabilities	5.72M	7.02M	5.4M	-	-
Total Liabilities	23.72M	18.92M	18.25M	14.65M	8.53M
Common Stock, Total	233K	407K	57.7K	74.36K	94K
Additional Paid In Capital	305M	330M	389M	398M	402M
Retained Earnings	-291M	-312M	-333M	-369M	-388M
Treasury Stock	-85.19K	-85.19K	-85.19K	-85.19K	-85.19K
Comprehensive Income and Other	42.78K	-	-7.97K	26.49K	60.8K
Total Common Equity	14.56M	18.61M	55.8M	29.33M	13.39M
Total Equity	14.56M	18.61M	55.8M	29.33M	13.39M
Total Liabilities And Equity	38.28M	37.53M	74.05M	43.98M	21.92M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.95M	5M	5.77M	9.09M	9.4M
ECS Total Common Shares Outstanding	1.55M	2.71M	5.77M	7.44M	9.4M
Book Value / Share	9.39	6.86	9.67	3.94	1.42
Tangible Book Value	-3.49M	3.16M	42.43M	29.33M	13.39M
Tangible Book Value Per Share	-2.25	1.16	7.35	3.94	1.42
Total Debt	11.34M	6.19M	6.63M	6.27M	1.62M
Net Debt	-3.53M	-10.97M	-42.76M	-26.48M	-14.07M
Debt Equivalent Oper. Leases	4.18M	4.18M	4.48M	4.7M	-
Account Code - Inventory Valuation	3	3	-	3	3
Machinery, Total	3.16M	3.18M	3.49M	2.82M	2.25M
Full Time Employees	29	27	29	31	33

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-16.85M	-21.48M	-20.77M	-35.9M	-19.51M
Depreciation & Amortization - CF	494K	514K	589K	732K	720K
Amortization of Goodwill and Intangible Assets - (CF)	227K	227K	114K	-	-
Depreciation & Amortization, Total	722K	742K	703K	732K	720K
Amortization of Deferred Charges, Total - (CF)	387K	447K	237K	181K	55.12K
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	34.3K
Asset Writedown & Restructuring Costs	-	2.37M	1.98M	13.37M	-
Stock-Based Compensation (CF)	2.29M	1.9M	3.76M	2.67M	759K
Other Operating Activities, Total	-4.61M	1.27M	-1.16M	-5.4M	991K
Change In Accounts Payable	-158K	-618K	302K	1.04M	-1.99M
Change in Unearned Revenues	-500K	-500K	-500K	-500K	-
Change in Other Net Operating Assets	-1.54M	254K	-773K	671K	-73.48K
Cash from Operations	-20.26M	-15.62M	-16.22M	-23.13M	-19.02M
Capital Expenditure	-349K	-19.09K	-312K	-268K	-452K
Cash Acquisitions	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	6.29M	7.94M	-29.81M	8.58M	11.46M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	5.94M	7.92M	-30.12M	8.32M	11.01M
Short Term Debt Issued, Total	-	1.32M	-	-	-
Long-Term Debt Issued, Total	-	-	5.76M	-	-
Total Debt Issued	-	1.32M	5.76M	-	-
Short Term Debt Repaid, Total	-	-1.32M	-	-	-
Long-Term Debt Repaid, Total	-	-5.2M	-5.19M	-	-6.42M
Total Debt Repaid	-	-6.52M	-5.19M	-	-6.42M
Issuance of Common Stock	7.84M	23.18M	54.2M	6.72M	2.78M
Issuance of Preferred Stock	-	-	-	28.5M	-
Repurchase of Preferred Stock	-	-	-	-28.5M	-
Cash from Financing	7.84M	17.98M	54.77M	6.72M	-3.64M
Net Change in Cash	-6.48M	10.29M	8.42M	-8.09M	-11.65M
Supplemental Items
Cash Interest Paid	761K	844K	357K	4.85M	180K
Cash Income Tax Paid (Refund)	-	-	-	-	-
Levered Free Cash Flow	-11.96M	-10.04M	-8.94M	-15.06M	-12.13M
Unlevered Free Cash Flow	-11.48M	-9.68M	-8.82M	-12.1M	-12.06M
Change In Net Working Capital	1.29M	750K	-122K	-310K	-11.47K
Net Debt Issued / Repaid	-	-5.2M	566K	-	-6.42M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-30.2	-30.48	-23.54	-26.39	-39.89
Return on Total Capital	-45.76	-45.58	-30.1	-31.78	-51.95
Return On Equity %	-95.15	-129.54	-55.83	-84.34	-91.37
Return on Common Equity	-95.15	-129.54	-55.83	-84.34	-91.37
Margin Analysis
Gross Profit Margin %	-2.51K	-2.17K	-2.02K	-2.25K	-
SG&A Margin	1.6K	1.53K	2.18K	2.74K	-
EBITDA Margin %	-3.97K	-3.55K	-4.06K	-4.84K	-
EBITA Margin %	-4.07K	-3.65K	-4.18K	-4.98K	-
EBIT Margin %	-4.11K	-3.7K	-4.2K	-4.98K	-
Income From Continuing Operations Margin %	-3.37K	-4.3K	-4.15K	-7.18K	-
Net Income Margin %	-3.37K	-4.3K	-4.15K	-7.18K	-
Net Avail. For Common Margin %	-3.37K	-4.3K	-4.15K	-7.18K	-
Normalized Net Income Margin	-2.68K	-2.46K	-2.7K	-3.69K	-
Levered Free Cash Flow Margin	-2.39K	-2.01K	-1.79K	-3.01K	-
Unlevered Free Cash Flow Margin	-2.3K	-1.94K	-1.76K	-2.42K	-
Asset Turnover
Asset Turnover	0.01	0.01	0.01	0.01	-
Fixed Assets Turnover	0.49	0.31	0.4	0.53	-
Short Term Liquidity
Current Ratio	2.06	2.79	7.67	3.7	2.47
Quick Ratio	1.89	2.54	7.31	3.28	2.12
Operating Cash Flow to Current Liabilities	-2.57	-2.31	-2.4	-2.3	-2.57
Average Days Payable Outstanding	82.18	82.39	82.36	95.4	-
Long Term Solvency
Total Debt/Equity	77.86	33.29	11.89	21.37	12.14
Total Debt / Total Capital	43.77	24.97	10.63	17.61	10.82
LT Debt/Equity	62.55	24.96	10.91	15.72	8.51
Long-Term Debt / Total Capital	35.17	18.72	9.75	12.95	7.59
Total Liabilities / Total Assets	61.97	50.41	24.65	33.31	38.92
EBIT / Interest Expense	-14.76	-14.3	-36.86	-4.96	-106.71
EBITDA / Interest Expense	-13.87	-13.33	-34.65	-4.69	-102.15
(EBITDA - Capex) / Interest Expense	-14.12	-13.34	-35.19	-4.75	-104.44
Total Debt / EBITDA	-0.59	-0.36	-0.34	-0.27	-0.08
Net Debt / EBITDA	0.18	0.64	2.17	1.12	0.7
Total Debt / (EBITDA - Capex)	-0.58	-0.36	-0.33	-0.26	-0.08
Net Debt / (EBITDA - Capex)	0.18	0.64	2.13	1.11	0.68
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	0	0	0	0	-
Gross Profit, 1 Yr. Growth %	18.93	-13.69	-6.69	11.01	-
EBITDA, 1 Yr. Growth %	-0.32	-10.58	14.42	19.14	-15.95
EBITA, 1 Yr. Growth %	1.5	-10.22	14.43	19.28	-15.61
EBIT, 1 Yr. Growth %	1.48	-10.11	13.64	18.63	-15.61
Earnings From Cont. Operations, 1 Yr. Growth %	41.81	27.49	-3.32	72.84	-45.64
Net Income, 1 Yr. Growth %	41.81	27.49	-3.32	72.84	-45.64
Normalized Net Income, 1 Yr. Growth %	4.05	-8.38	9.69	36.78	-30.61
Diluted EPS Before Extra, 1 Yr. Growth %	14.2	-12.91	-62.04	31.32	-57.07
Net Property, Plant and Equip., 1 Yr. Growth %	894.98	-26.95	-12.96	-39.71	233.29
Total Assets, 1 Yr. Growth %	-18.31	-1.96	97.31	-40.61	-50.16
Tangible Book Value, 1 Yr. Growth %	-235.44	-190.29	1.24K	-30.88	-54.35
Common Equity, 1 Yr. Growth %	-30.21	27.83	199.8	-47.44	-54.35
Cash From Operations, 1 Yr. Growth %	187.7	-22.9	3.87	42.58	-17.64
Capital Expenditures, 1 Yr. Growth %	152.28	-94.53	1.53K	-14.06	68.69
Levered Free Cash Flow, 1 Yr. Growth %	40.24	-16.04	-11.02	68.59	-17.41
Unlevered Free Cash Flow, 1 Yr. Growth %	38.56	-15.63	-8.93	37.27	2.87
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	0	0	0	0	-
Gross Profit, 2 Yr. CAGR %	-0.05	1.31	-10.26	1.78	-
EBITDA, 2 Yr. CAGR %	5.24	-5.59	1.15	16.76	1.17
EBITA, 2 Yr. CAGR %	5.59	-4.54	1.36	16.83	0.33
EBIT, 2 Yr. CAGR %	5.52	-4.49	1.07	16.11	0.06
Earnings From Cont. Operations, 2 Yr. CAGR %	-9.12	34.46	11.02	29.27	-3.07
Net Income, 2 Yr. CAGR %	-9.12	34.46	11.02	29.27	-3.07
Normalized Net Income, 2 Yr. CAGR %	7.61	-2.37	0.25	22.49	-2.58
Diluted EPS Before Extra, 2 Yr. CAGR %	-46.73	-0.27	-42.51	-29.4	-24.92
Net Property, Plant and Equip., 2 Yr. CAGR %	223.28	169.59	-20.26	-27.56	41.75
Total Assets, 2 Yr. CAGR %	-10.24	-10.51	39.08	8.25	-45.59
Tangible Book Value, 2 Yr. CAGR %	-2.64	10.58	248.45	204.88	-43.83
Common Equity, 2 Yr. CAGR %